Publications by authors named "Tamar Hamburger"

40Publications

Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.

Lung Cancer 2019 11 12;137:48-51. Epub 2019 Sep 12.

Sharett institute of Oncology, Hebrew University-Hadassah Medical Center, Jerusalem, 91120, Israel. Electronic address:

View Article and Find Full Text PDF
November 2019

Correction: Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma.

Oncotarget 2018 11 16;9(90):36250. Epub 2018 Nov 16.

Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem, Jerusalem, Israel.

View Article and Find Full Text PDF
November 2018

Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies.

Surgeon 2018 Oct 21;16(5):278-282. Epub 2018 Feb 21.

Department of Surgery B, Chaim Sheba Medical Center, Tel-Hashomer, Israel; Affiliated to the Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

View Article and Find Full Text PDF
October 2018

Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers.

Eur J Hum Genet 2018 03 10;26(3):382-386. Epub 2018 Jan 10.

Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

View Article and Find Full Text PDF
March 2018

Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma.

Oncotarget 2017 Sep 22;8(39):65186-65198. Epub 2017 May 22.

Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem, Jerusalem, Israel.

View Article and Find Full Text PDF
September 2017

Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis.

Onco Targets Ther 2017 29;10:1889-1896. Epub 2017 Mar 29.

Sharett Institute of Oncology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.

View Article and Find Full Text PDF
March 2017

Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.

Int J Cancer 2017 05 8;140(9):2145-2149. Epub 2017 Feb 8.

Sharett Institute of Oncology, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.

View Article and Find Full Text PDF
May 2017

Heparanase augments insulin receptor signaling in breast carcinoma.

Oncotarget 2017 Mar;8(12):19403-19412

Sharett Institute, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel.

View Article and Find Full Text PDF
March 2017

Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.

J Immunother 2016 10;39(8):321-8

*Sharett Institute of Oncology, Hadassah Hebrew University Hospital ‡Department of Oncology, Shaare Zedek Medical Center, Jerusalem †Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv §Tumor Immunology and Immunotherapy Lab, Bar Ilan University, Ramat Gan, Israel.

View Article and Find Full Text PDF
October 2016

A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.

Breast 2014 Aug 14;23(4):435-8. Epub 2014 May 14.

Oncology Dept., Hadassah Hebrew University Medical Center, Israel.

View Article and Find Full Text PDF
August 2014

An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group.

Target Oncol 2015 Mar 6;10(1):55-63. Epub 2014 Mar 6.

Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, P.O. box 12000, Jerusalem, Israel, 91120,

View Article and Find Full Text PDF
March 2015

Prospective validation of a surgical complications grading system in a cohort of 2114 patients.

J Surg Res 2014 May 13;188(1):30-6. Epub 2013 Dec 13.

Department of Surgery, Hadassah-Hebrew University Medical Center, Mount Scopus, Jerusalem, Israel. Electronic address:

View Article and Find Full Text PDF
May 2014

Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer.

Cancer Epidemiol Biomarkers Prev 2013 Nov 21;22(11):2110-5. Epub 2013 Aug 21.

Authors' Affiliations: Departments of Oncology, Surgery, and Pathology, Hadassah and Hebrew University Medical Centre, Jerusalem, Israel; and Group of Clinical Virology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

View Article and Find Full Text PDF
November 2013

Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.

Breast Cancer Res Treat 2013 Jul 4;140(1):207-11. Epub 2013 Jul 4.

Sharett Institute of Oncology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.

View Article and Find Full Text PDF
July 2013

Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer.

Breast Cancer Res Treat 2013 Apr 28;138(2):407-13. Epub 2013 Feb 28.

Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Ein Kerem, P.O. Box 12000, Jerusalem, 91120, Israel.

View Article and Find Full Text PDF
April 2013

The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer.

Anticancer Res 2013 Jan;33(1):293-9

Department of Oncology, Hadassah and Hebrew University Medical Centre, P.O. Box 12000, Jerusalem 91120, Israel.

View Article and Find Full Text PDF
January 2013